How to Get Prescribed Zepbound: The Complete Eligibility, Lab, and Access Protocol for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound requires either BMI ≥30, or BMI ≥27 with one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• Most providers require baseline labs (A1C, lipid panel, TSH, creatinine) and blood pressure measurement before prescribing
• Insurance coverage requires prior authorization in 94% of commercial plans, with approval rates around 40% for obesity indication without diabetes
• Compounded tirzepatide through telehealth platforms bypasses insurance but requires the same clinical eligibility criteria and provider evaluation

Direct answer (40-60 words)

Getting prescribed Zepbound requires meeting FDA-approved BMI thresholds (≥30, or ≥27 with comorbidities), completing baseline lab work, and provider evaluation. You can pursue coverage through insurance (requires prior authorization), pay cash for brand-name ($1,060/month list price), or access compounded tirzepatide through telehealth platforms ($299-$499/month). All paths require a licensed provider prescription.

Table of contents

1. The FDA-approved eligibility criteria (what qualifies you)
2. The required baseline evaluation (labs, vitals, history)
3. The four prescription pathways: insurance, cash-pay brand, telehealth compounded, and in-person compounded
4. What most articles get wrong about BMI requirements
5. The prior authorization process for insurance coverage
6. How telehealth platforms evaluate eligibility differently than traditional clinics
7. Contraindications that disqualify you from tirzepatide
8. The decision tree: which pathway matches your situation
9. Timeline expectations for each pathway
10. What happens after you get the prescription
11. When you should NOT pursue Zepbound
12. FAQ

The FDA-approved eligibility criteria (what qualifies you)

Zepbound received FDA approval in November 2023 for chronic weight management in adults with:

Primary indication:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition

Qualifying comorbidities for the BMI ≥27 threshold:

• Type 2 diabetes
• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (history of MI, stroke, or established coronary artery disease)

These criteria come directly from the SURMOUNT-1 and SURMOUNT-2 trial inclusion criteria and the FDA label (Jastreboff et al., New England Journal of Medicine, 2022). Every legitimate prescriber, whether insurance-based or telehealth, uses these thresholds.

Age requirements:

• FDA-approved for adults 18 and older
• Not approved for pediatric use (tirzepatide trials in adolescents are ongoing but not yet published)

Weight loss requirement:

• No minimum weight loss requirement from prior attempts
• No requirement to have "failed" other medications first (though insurance often requires documented diet/exercise attempts)

The BMI calculation is weight in kilograms divided by height in meters squared. A 5'6" person qualifies at 186 pounds (BMI 30). A 5'10" person qualifies at 209 pounds.

The required baseline evaluation (labs, vitals, history)

Before prescribing Zepbound or compounded tirzepatide, most providers require:

Mandatory measurements:

• Height and weight (to calculate BMI)
• Blood pressure
• Heart rate

Standard baseline labs:

• Hemoglobin A1C (screens for diabetes and prediabetes)
• Comprehensive metabolic panel (kidney function, electrolytes)
• Lipid panel (cholesterol, triglycerides, LDL, HDL)
• Thyroid-stimulating hormone (TSH)

Additional labs in specific situations:

• Pregnancy test (required for women of childbearing age; tirzepatide is contraindicated in pregnancy)
• Liver function tests (ALT, AST) if history of fatty liver disease
• Amylase and lipase if history of pancreatitis
• Calcitonin if personal or family history of medullary thyroid carcinoma

The lab requirement exists for two reasons. First, safety screening: elevated creatinine signals kidney disease, which changes dosing considerations. Elevated lipase suggests pancreatitis risk. Second, baseline documentation: A1C and lipid values establish a starting point to measure treatment benefit.

Most telehealth platforms include lab orders as part of the intake process. You visit a local LabCorp or Quest, results route to the prescriber, and evaluation happens within 48 to 72 hours. Traditional clinics usually order labs at the initial visit and schedule a follow-up to review results and write the prescription.

The four prescription pathways: insurance, cash-pay brand, telehealth compounded, and in-person compounded

Pathway 1: Insurance coverage for brand-name Zepbound

• Requires prior authorization in 94% of commercial plans (IQVIA data, 2024)
• Provider submits PA request with documentation of BMI, comorbidities, and prior weight loss attempts
• Approval timeline: 3 to 14 business days
• Approval rate for obesity indication (no diabetes): approximately 40%
• Approval rate for obesity + type 2 diabetes: approximately 68%
• Out-of-pocket cost if approved: $25 to $500/month depending on plan tier and copay assistance eligibility
• Eli Lilly savings card covers up to $550/month for commercially insured patients (not available for Medicare/Medicaid)

Pathway 2: Cash-pay brand-name Zepbound

• No prior authorization required
• List price: $1,059.87/month (as of April 2026)
• Eli Lilly savings card does NOT apply to cash-pay patients
• Prescription written by any licensed provider
• Filled at retail pharmacy
• Timeline: prescription to first dose in 1 to 3 days

Pathway 3: Telehealth platform with compounded tirzepatide

• Asynchronous or synchronous virtual consultation
• Provider reviews health history, current medications, baseline labs
• Prescription sent to affiliated compounding pharmacy
• Medication shipped directly to patient
• Cost: $299 to $499/month (varies by platform and dose)
• Timeline: consultation to first dose in 5 to 10 days
• Requires ongoing monthly subscription and periodic provider check-ins

Pathway 4: In-person provider with local compounding pharmacy

• Traditional clinic visit with PCP, endocrinologist, or obesity medicine specialist
• Prescription sent to local compounding pharmacy (patient identifies pharmacy or provider recommends one)
• Patient picks up medication locally
• Cost: $250 to $600/month depending on pharmacy and dose
• Timeline: visit to first dose in 3 to 7 days

Pathway	Typical cost/month	Timeline to first dose	Prior auth required	Provider type
Insurance + brand Zepbound	$25-$500	7-21 days	Yes	Any MD/DO/NP/PA
Cash brand Zepbound	$1,060	1-3 days	No	Any MD/DO/NP/PA
Telehealth compounded	$299-$499	5-10 days	No	Platform-affiliated
In-person compounded	$250-$600	3-7 days	No	Any prescriber

What most articles get wrong about BMI requirements

The most common error in published content on Zepbound eligibility is the claim that "you must try diet and exercise first" or "you must fail other weight loss medications before qualifying."

This is not an FDA requirement. The FDA label for Zepbound states it is indicated "as an adjunct to a reduced-calorie diet and increased physical activity" but does not require documented prior attempts or failures.

The confusion comes from insurance prior authorization policies, which often DO require documentation of:

• 3 to 6 months of supervised diet and exercise with less than 5% weight loss, OR
• Trial and failure of at least one other weight loss medication (orlistat, phentermine, naltrexone-bupropion)

This is a payer policy, not a clinical or regulatory requirement. If you are paying cash (brand or compounded), no prior attempt documentation is required. You meet the BMI threshold, you get the prescription.

The second common error is conflating the BMI ≥27 threshold with "anyone who wants to lose 10 to 15 pounds." The ≥27 threshold requires a documented comorbidity. A 5'8" person at 180 pounds (BMI 27.4) who is otherwise healthy does not qualify under FDA labeling. The same person with documented hypertension or prediabetes (A1C 5.7 to 6.4%) does qualify.

Telehealth platforms vary in how strictly they interpret the comorbidity requirement. Some accept patient-reported hypertension history. Others require documented blood pressure readings ≥130/80 on two separate occasions or current antihypertensive medication. The clinical standard is objective documentation, not patient self-report.

The prior authorization process for insurance coverage

If you are pursuing insurance coverage for brand-name Zepbound, here is the step-by-step PA process:

Step 1: Provider initiates prior authorization request

The prescribing provider (or their office staff) submits a PA form to your insurance plan. This form includes:

• Diagnosis codes (E66.9 for obesity, E66.01 for morbid obesity, plus codes for comorbidities)
• Current BMI with height and weight documentation
• Documentation of weight-related comorbidities
• Documentation of prior weight loss attempts (diet, exercise, behavioral counseling)
• Baseline lab values (A1C, lipid panel)
• Statement of medical necessity

Step 2: Insurance reviews the request

The insurance plan's pharmacy benefit manager (PBM) reviews the request against their coverage policy. Most plans require:

• BMI ≥30, or BMI ≥27 with comorbidity (matches FDA criteria)
• Documented supervised weight loss attempt within the past 6 to 12 months with less than 5% weight loss
• No contraindications (personal or family history of medullary thyroid carcinoma, history of pancreatitis, pregnancy)

Step 3: Approval, denial, or request for additional information

• Approved: Prescription is covered at the plan's formulary tier (usually tier 3 or specialty tier). Patient receives approval letter with copay amount.
• Denied: Most common reasons are insufficient documentation of prior weight loss attempts, BMI below threshold, or lack of documented comorbidity. Patient and provider receive denial letter with specific reason.
• Additional information requested: Plan requests more documentation (weight logs, prior medication trials, additional lab work). Provider has 5 to 10 business days to submit.

Step 4: Appeal process (if denied)

Patients have the right to appeal. The provider submits a letter of medical necessity explaining why the medication is clinically appropriate despite the denial reason. Peer-to-peer review (provider speaks directly with the plan's medical director) is sometimes available. Appeal timelines are 30 to 60 days.

Approval rates by indication (IQVIA 2024 data):

• Obesity alone (no diabetes): 38% to 42%
• Obesity + type 2 diabetes: 65% to 70%
• Overweight (BMI 27-29.9) + comorbidity: 25% to 35%

The lower approval rate for obesity alone reflects payer reluctance to cover GLP-1 medications for weight loss rather than diabetes, despite FDA approval for both indications.

How telehealth platforms evaluate eligibility differently than traditional clinics

Telehealth platforms specializing in compounded GLP-1 medications operate under the same clinical eligibility criteria but differ in process and documentation requirements.

Asynchronous intake: Most platforms use a questionnaire-based intake. You enter height, weight, medical history, current medications, and weight loss goals. A provider reviews the intake within 24 to 48 hours. If you meet criteria, the prescription is issued. If borderline or additional information is needed, the platform requests a synchronous video visit.

Lab requirements: Some platforms require labs before prescribing. Others prescribe first and require labs within 30 days of starting treatment. The clinical standard is baseline labs before starting, but regulatory enforcement varies by state. Platforms operating in states with stricter telemedicine regulations (California, New York, Texas) are more likely to require labs upfront.

BMI verification: Most platforms accept patient-reported height and weight. Some require a photo of a scale reading or a video visit where you step on a scale. The honor system is common but creates eligibility variability.

Comorbidity documentation: For patients with BMI 27 to 29.9, platforms vary in how they verify comorbidities. Some accept patient self-report of hypertension or high cholesterol. Others require uploading recent lab results or medication lists showing antihypertensive or statin prescriptions. The stricter the documentation requirement, the closer the platform operates to traditional clinical standards.

Contraindication screening: All platforms screen for absolute contraindications (pregnancy, personal or family history of medullary thyroid carcinoma, history of pancreatitis). Most screen for relative contraindications (active gallbladder disease, severe gastroparesis, diabetic retinopathy). The depth of screening correlates with platform clinical rigor.

FormBlends clinical pattern observation: Across intake evaluations, the most common eligibility gap is patients with BMI 27 to 29.9 who believe they qualify but lack a documented comorbidity. Self-reported "high cholesterol" or "borderline blood pressure" often does not meet the threshold when labs or BP readings are reviewed. The second most common gap is patients with BMI 25 to 26.9 who do not meet any FDA-approved threshold but have seen social media content suggesting GLP-1s are appropriate for cosmetic weight loss. Clear communication of clinical criteria at intake reduces frustration and sets appropriate expectations.

Contraindications that disqualify you from tirzepatide

Absolute contraindications (you cannot take tirzepatide):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning pregnancy within the next 12 months
• Breastfeeding
• Known hypersensitivity to tirzepatide or any excipient

Relative contraindications (requires provider evaluation and shared decision-making):

• History of pancreatitis (GLP-1 receptor agonists carry a small but documented pancreatitis risk; Azoulay et al., JAMA Internal Medicine, 2016)
• Active gallbladder disease or history of gallstones (rapid weight loss increases gallstone risk)
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Diabetic retinopathy (some evidence of worsening retinopathy with rapid glucose reduction; SUSTAIN-6 trial, Marso et al., New England Journal of Medicine, 2016)
• Chronic kidney disease stage 4 or 5 (eGFR <30 mL/min; limited safety data in advanced CKD)
• History of suicidal ideation or severe depression (ongoing monitoring of GLP-1 medications for neuropsychiatric effects; FDA issued investigation notice in 2023)

Medication interactions requiring caution:

• Insulin or sulfonylureas (increased hypoglycemia risk; dose reduction of these medications usually required)
• Oral medications with narrow therapeutic windows (tirzepatide delays gastric emptying, which can affect absorption of levothyroxine, oral contraceptives, and some antibiotics)

If you have any relative contraindication, disclosure during the intake process is required. Providers weigh the contraindication severity against the benefit of weight loss. For example, a patient with a remote history of pancreatitis (10+ years ago, resolved, no recurrence) may still be a candidate with close monitoring. A patient with pancreatitis in the past 12 months is not.

The decision tree: which pathway matches your situation

Start here: Do you have insurance that covers prescription medications?

• Yes → Does your BMI qualify (≥30, or ≥27 with comorbidity)?
• Yes → Is your provider willing to submit a prior authorization?
• Yes → Pursue insurance pathway. Expect 7 to 21 days. If denied, proceed to appeal or switch to compounded pathway.
• No → Pursue cash-pay brand ($1,060/month) or compounded pathway ($299-$499/month).
• No → You do not meet clinical eligibility. Discuss alternative weight management options with your provider.

• No → Do you meet BMI criteria (≥30, or ≥27 with comorbidity)?
• Yes → Choose between cash-pay brand ($1,060/month) or compounded tirzepatide ($299-$499/month). Compounded is the cost-effective choice for most patients.
• No → You do not meet clinical eligibility.

If you meet criteria and are choosing between brand and compounded:

• Choose brand-name Zepbound if:
• You have insurance coverage with manageable copay
• You prefer FDA-approved formulation
• You have access to Eli Lilly savings card (commercially insured, not Medicare/Medicaid)

• Choose compounded tirzepatide if:
• You are paying out of pocket
• Your insurance denied coverage and appeal failed
• You prefer telehealth convenience over in-person visits
• Cost is a primary concern ($299-$499/month vs $1,060/month)

If you are on the BMI borderline (27 to 29.9):

You need documented comorbidity. If you have hypertension, get two BP readings ≥130/80 documented. If you have prediabetes, get an A1C test (≥5.7% qualifies). If you have dyslipidemia, get a lipid panel showing LDL ≥130 mg/dL or triglycerides ≥150 mg/dL. Objective documentation is the difference between qualifying and not qualifying.

Timeline expectations for each pathway

Insurance + brand-name Zepbound:

• Day 0: Initial provider visit, labs ordered
• Day 3-7: Lab results reviewed, prescription written, prior authorization submitted
• Day 10-21: PA approval or denial
• Day 21-24: If approved, prescription sent to pharmacy, medication dispensed
• Total timeline: 21 to 28 days from initial visit to first dose

Cash-pay brand-name Zepbound:

• Day 0: Provider visit, labs ordered (or reviewed if recent)
• Day 1-3: Labs reviewed, prescription written and sent to pharmacy
• Day 1-3: Pharmacy fills prescription, patient picks up
• Total timeline: 1 to 6 days from visit to first dose

Telehealth platform with compounded tirzepatide:

• Day 0: Online intake completed
• Day 1-2: Provider reviews intake, requests labs if needed
• Day 3-5: Labs completed (if required) and reviewed
• Day 5-7: Prescription issued, sent to compounding pharmacy
• Day 7-10: Medication compounded and shipped
• Total timeline: 7 to 12 days from intake to first dose

In-person provider with local compounding pharmacy:

• Day 0: Provider visit, labs ordered or reviewed
• Day 1-3: Prescription sent to compounding pharmacy
• Day 3-7: Medication compounded, patient notified for pickup
• Total timeline: 3 to 10 days from visit to first dose

The telehealth pathway is slower than cash-pay brand but faster than insurance PA. The in-person compounded pathway is the most variable, depending on the compounding pharmacy's turnaround time.

What happens after you get the prescription

For brand-name Zepbound:

You receive a carton containing four single-dose auto-injector pens (one month supply at starting dose). Each pen is pre-filled and pre-set to the prescribed dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). You inject once weekly, subcutaneously, in the abdomen, thigh, or upper arm. Rotate injection sites each week.

For compounded tirzepatide:

You receive a vial of lyophilized (freeze-dried) tirzepatide powder, a vial of bacteriostatic water, syringes, needles, and alcohol wipes. You reconstitute the medication by injecting bacteriostatic water into the tirzepatide vial, then draw the prescribed dose into a syringe and inject subcutaneously once weekly. Detailed reconstitution instructions are included.

Titration schedule:

Both brand and compounded tirzepatide follow the same dose escalation schedule to minimize nausea and GI side effects:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional; some patients stay at 5 mg)
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly (optional)
• Weeks 21+: 15 mg once weekly (maximum dose)

Most patients reach their effective dose between 5 mg and 10 mg. The 15 mg dose is reserved for patients who need additional weight loss and tolerate lower doses well.

Follow-up requirements:

• Month 1: Provider check-in (virtual or in-person) to assess tolerance and side effects
• Month 3: Repeat labs (A1C, lipid panel, CMP) and weight check
• Month 6: Comprehensive evaluation of weight loss progress, side effects, and decision to continue or adjust dose
• Ongoing: Monthly or quarterly check-ins depending on provider protocol

When you should NOT pursue Zepbound

Clinical situations where Zepbound is not the right choice:

1. You are trying to lose the last 5 to 10 pounds for cosmetic reasons.

If your BMI is below 27 and you have no comorbidities, you do not meet clinical eligibility. GLP-1 medications are powerful tools for obesity and metabolic disease, not cosmetic weight management. The side effect burden (nausea, fatigue, potential muscle loss) does not justify use outside FDA-approved indications.

2. You have a history of disordered eating or active eating disorder.

GLP-1 medications suppress appetite powerfully. In patients with anorexia nervosa, bulimia, or binge eating disorder, this can worsen disordered eating patterns or trigger relapse. Weight management in eating disorder patients requires specialized psychiatric and nutritional support, not appetite suppression.

3. You are pregnant, planning pregnancy within 12 months, or breastfeeding.

Tirzepatide is contraindicated in pregnancy. Animal studies showed fetal harm. If you are planning pregnancy, discontinue tirzepatide at least 2 months before attempting conception (based on the medication's half-life and washout period). There is no data on tirzepatide in breast milk; breastfeeding patients should not use it.

4. You are not willing or able to commit to weekly injections.

Adherence to weekly dosing is required for efficacy. If you frequently miss doses, the medication does not work. Patients with needle phobia, chaotic schedules, or poor medication adherence are better candidates for oral options (if and when they become available) or behavioral weight management.

5. You expect the medication to work without diet or exercise changes.

Tirzepatide is an adjunct to lifestyle modification, not a replacement. Patients who continue high-calorie diets and sedentary behavior lose less weight and regain faster after discontinuation. The SURMOUNT trials required reduced-calorie diets and 150 minutes/week of physical activity. Real-world outcomes are worse without those components.

6. You cannot afford ongoing treatment.

Tirzepatide is not a short-term medication. Weight regain after discontinuation is common (SURMOUNT-4 withdrawal study showed patients regained 14% of body weight within 52 weeks of stopping; Aronne et al., JAMA, 2024). If you cannot sustain $299 to $1,060/month indefinitely, the cost-benefit calculus changes. Discuss this openly with your provider before starting.

FAQ

What BMI do I need to get prescribed Zepbound? You need BMI ≥30 (obesity), or BMI ≥27 (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. These are the FDA-approved criteria and apply to both brand-name and compounded tirzepatide.

Can I get Zepbound without seeing a doctor in person? Yes. Telehealth platforms can prescribe Zepbound or compounded tirzepatide after a virtual consultation. You complete an online intake, a licensed provider reviews your information and labs, and if you qualify, the prescription is issued. Most platforms operate in all 50 states.

Do I need a referral to get prescribed Zepbound? No. Any licensed prescriber (MD, DO, NP, PA) can prescribe Zepbound. You do not need a referral to an endocrinologist or obesity medicine specialist. Your primary care provider, a telehealth platform provider, or a weight management clinic can all prescribe it.

How long does it take to get approved for Zepbound through insurance? Prior authorization typically takes 7 to 14 business days. Some plans respond in 3 to 5 days; others take up to 21 days. If additional documentation is requested, add another 5 to 10 days. Total timeline from PA submission to approval is usually 10 to 21 days.

What labs do I need before starting Zepbound? Most providers require hemoglobin A1C, comprehensive metabolic panel (kidney function), lipid panel, and TSH. Women of childbearing age need a pregnancy test. Additional labs (liver function, amylase, lipase) may be required based on your medical history.

Can I get Zepbound if my BMI is 26? Not under current FDA labeling. BMI 26 does not meet the ≥27 threshold. Even with comorbidities, you need BMI ≥27 to qualify. Some patients pursue off-label prescribing, but most legitimate providers adhere to FDA criteria.

Does insurance cover Zepbound for weight loss? Some plans do, but most require prior authorization and many deny coverage for obesity indication without diabetes. Approval rates are approximately 40% for obesity alone, 68% for obesity plus type 2 diabetes. Medicare does not cover GLP-1 medications for weight loss under Part D (as of April 2026).

How much does Zepbound cost without insurance? Brand-name Zepbound costs $1,059.87/month at list price. Compounded tirzepatide through telehealth platforms costs $299 to $499/month. Local compounding pharmacies charge $250 to $600/month depending on dose and location.

Can I use a coupon or savings card for Zepbound? Eli Lilly offers a savings card covering up to $550/month for commercially insured patients. The card does not apply to Medicare, Medicaid, or cash-pay patients. If your insurance covers Zepbound, the savings card reduces your copay to as low as $25/month.

What is the difference between Zepbound and compounded tirzepatide? Zepbound is the FDA-approved brand-name product manufactured by Eli Lilly. Compounded tirzepatide is prepared by a compounding pharmacy using the same active ingredient but is not FDA-approved. Both contain tirzepatide and work the same way. Compounded versions cost less but lack the regulatory oversight of FDA-approved drugs.

Do I have to try other weight loss medications before Zepbound? Not according to FDA labeling. However, many insurance plans require documented trial and failure of at least one other weight loss medication (orlistat, phentermine, naltrexone-bupropion) before approving Zepbound. If you are paying cash or using compounded tirzepatide, no prior medication trial is required.

Can I get Zepbound if I have prediabetes? Yes, if your BMI is ≥30. If your BMI is 27 to 29.9, prediabetes (A1C 5.7% to 6.4%) qualifies as a comorbidity under most clinical interpretations, though it is not explicitly listed in the FDA label. Providers vary in how they interpret this; some accept prediabetes, others require full diabetes diagnosis or a different listed comorbidity.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight (SURMOUNT-2). New England Journal of Medicine. 2023.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Azoulay L et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. JAMA Internal Medicine. 2016.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. FDA. Zepbound (tirzepatide) Prescribing Information. November 2023.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. IQVIA Institute. GLP-1 Receptor Agonist Market Access and Utilization Report. 2024.
11. Eli Lilly and Company. Zepbound Savings Card Terms and Conditions. 2024.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. LabCorp and Quest are registered trademarks of Laboratory Corporation of America and Quest Diagnostics. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.